Summary
Direxion Daily Biotech Top 5 Bull 2X ETF is an ETF - a fund traded on an exchange like a stock - run by Direxion. Positions inside: 11. The ten largest make up 241% of the fund.
- Yearly costs
- 6.27%
- Fund size
- $2.97M
- Positions
- 11
- Dividend yield
- 0.67%
- Running since
- 2025
What speaks for it
Nothing stands out in its favour.
What to watch
- The ten largest positions make up 241% of the fund, so its result rests on a few names.
- Costs of 6.27% a year are above the middle of comparable funds (0.44%).
- A young fund: it has been running only since 2025.
- A small fund with $2.97M under management; small funds get closed more often.
- It trades little: only about $142.0K changes hands a day.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- -3.5%
- 3 months
- +18%
- This year
- +22%
- 1 year
- +33%
- Avg. market cap
- $143.4B
- P/E
- 26.0x
- Forward P/E
- 19.1x
- P/S
- 7.0x
- P/B
- 6.3x
- P/FCF
- 23.8x
- EV/EBITDA
- 24.0x
- Dividend yield
- 1.08%
- ROIC
- 9.5%
- ROE
- 27.0%
- Gross margin
- 81.9%
- Operating margin
- 23.2%
- Net margin
- 20.4%
- Payout ratio
- 28.0%
- Net debt/EBITDA
- 7.8x
- Beta
- -0.18
Weighted average of the 5 largest companies, which make up 55% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Concentrated- 1 BIOEW5 SWAP ASSET LEG (BIOEW5MLL) 59%
- 2 BIOEW5 SWAP ASSET LEG (BIOEW5BCL) 49%
- 3 BIOEW5 SWAP ASSET LEG (BIOEW5CTL) 37%
- 4 DREYFUS GOVT CASH MAN INS 30%
- 5 AMAmgen AMGN 12%
- 6 GIGilead Sciences GILD 12%
- 7 RERegeneron Pharmaceuticals REGN 11%
- 8 VRVertex Pharmaceuticals VRTX 11%
- 9 GOLDMAN FINL SQ TRSRY INST 506 11%
- 10 ARArgenx ARGX 9.2%
Positions in the fund: 11. The ten largest make up 241% of it.
Composition as of Oct 18, 2026.
Where is it spread?
Spread outBy country
- United States 19%
- Netherlands 3.7%
- Other countries 78%
By company size
- Mega cap 22%
- Large cap 78%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M. Counted from the companies that make up 55% of the fund.
Largest country: United States (19%). Largest size group: Large cap (78%).
What does it cost me?
Expensive- A year from $10,000
- $627
- Over 20 years
- $18,789
From every $10,000 invested the fund takes $627 a year. You do not pay it separately - it is taken out of the fund's value. Over 20 years at 5% yearly growth that adds up to about $18,789.
How has it done?
Growing over the long run- Over the last year
- +33%
- Deepest drop
- -27%
- Yearly volatility
- 44%
Growth over the last year: 33%. Deepest drop in these years: 27% below the earlier high.
Does it pay dividends?
Yes, it pays out- Yield
- 0.67%
- Last payment
- $0.14
Over the last 12 months it paid $0.25 per share, which is 0.67% of today's price. The last payment was $0.14 on Sep 22, 2026.
Is it easy to buy and sell?
It trades little- Traded a day
- $142.0K
- Shares a day
- 3.7K
On an average day about $142.0K of the fund changes hands.
How expensive are the companies inside?
Rather expensive- P/E of the companies inside
- 26.0
- Average Bulios Score
- 61 out of 100
Weight by Bulios Fair Price
- Undervalued 58%
- Fairly valued 22%
- Overvalued 19%
On average the companies inside trade for 26.0 times their yearly profit. By Fair Price, 58% of the rated weight comes out as undervalued.
Counted from its largest companies (5), which make up 55% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Similar funds
Funds that hold much of the same. The overlap says how much of their weight they share with this fund.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
BB BBH VanEck Biotech ETF | United States | 0.35% | $486.7M | +35% | Pays out | 43% |
IB IBB iShares Biotechnology ETF | United States | 0.44% | $10.5B | +30% | Pays out | 33% |
SB SBIO.MI Invesco NASDAQ Biotech UCITS ETF | Ireland | 0.40% | $568.8M | +37% | Reinvests | 31% |
IB IBBQ Invesco Nasdaq Biotechnology ETF | United States | 0.19% | $79.9M | +30% | Pays out | 31% |
2B 2B70.DE iShares Nasdaq US Biotechnology UCITS ETF | Ireland | 0.35% | $906.2M | +37% | Reinvests | 31% |
20 203780.KS MiraeAsset TIGER NASDAQ BIO ETF | South Korea | 0.30% | $76.4M | +22% | Reinvests | 31% |
